Make drug discovery faster and more efficient by laying a solid data foundation to fuse DEL and ML technology
Anagenex is a drug discovery company combining DNA encoded library (DEL) technology with machine learning (ML) to achieve their vision of finding a drug candidate for every disease cheaply and quickly. Their goal is to replace the traditionally time- and labor-intensive portion of drug discovery with this fast and powerful approach based on combinatorial chemistry and artificial intelligence.
Results
100%
of scientists agree that Benchling has helped connect bench and ML work together
50%
decrease in time spent on data entry and cleanup
200%
estimated increase in speed due to starting with a robust data infrastructure
Challenges
| Edge use cases | Treating DNA sequencing readouts as an intermediary step to understanding the molecule of interest is an atypical use case, creating an additional layer of complexity. |
|---|---|
| Batch effect identification | It was difficult to accurately classify biologically relevant effects vs. batch effects in new areas of ML usage. |
| Scalable solution | Anagenex needed a robust solution that could start tracking from the very first experiments and scale quickly as the company grows. |
Powering breakthroughs for over 1,200 biotechnology companies, from startups to Fortune 500s
